Your browser doesn't support javascript.
loading
Attrition Rates in Multiple Myeloma Treatment under Real World Conditions-An Analysis from the Austrian Myeloma Registry (AMR).
Benda, Magdalena A; Ulmer, Hanno; Weger, Roman; Reimann, Patrick; Lang, Theresia; Pichler, Petra; Winder, Thomas; Hartmann, Bernd; Strassl, Irene; Krauth, Maria Theresa; Agis, Hermine; Sormann, Siegfried; Podar, Klaus; Willenbacher, Wolfgang; Willenbacher, Ella.
Afiliación
  • Benda MA; Internal Medicine II: Oncology, Hematology, Gastroenterology, Infectiology, Academic Teaching Hospital Feldkirch, 6800 Feldkirch, Austria.
  • Ulmer H; Private University of the Principality of Liechtenstein, 9495 Triesen, Principality of Liechtenstein.
  • Weger R; Institute of Medical Statistics and Informatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
  • Reimann P; Internal Medicine V: Haematology & Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
  • Lang T; syndena GmbH, Connect to Cure, 6020 Innsbruck, Austria.
  • Pichler P; Internal Medicine II: Oncology, Hematology, Gastroenterology, Infectiology, Academic Teaching Hospital Feldkirch, 6800 Feldkirch, Austria.
  • Winder T; Private University of the Principality of Liechtenstein, 9495 Triesen, Principality of Liechtenstein.
  • Hartmann B; Internal Medicine II: Oncology, Hematology, Gastroenterology, Infectiology, Academic Teaching Hospital Feldkirch, 6800 Feldkirch, Austria.
  • Strassl I; Internal Medicine I: Hematology, Oncology, Nephrology & Endocrinology St. Pölten, Medical University of St. Pölten, 3100 St. Pölten, Austria.
  • Krauth MT; Internal Medicine II: Oncology, Hematology, Gastroenterology, Infectiology, Academic Teaching Hospital Feldkirch, 6800 Feldkirch, Austria.
  • Agis H; Internal Medicine II: Oncology, Hematology, Gastroenterology, Infectiology, Academic Teaching Hospital Feldkirch, 6800 Feldkirch, Austria.
  • Sormann S; Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1 and Seilerstätte 4, 4020 Linz, Austria.
  • Podar K; Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria.
  • Willenbacher W; Department of Internal Medicine I, Division Hematology & Hemostaseology, Medical University Vienna, 1090 Wien, Austria.
  • Willenbacher E; Department of Internal Medicine I, Division Hematology & Hemostaseology, Medical University Vienna, 1090 Wien, Austria.
Cancers (Basel) ; 15(3)2023 Feb 02.
Article en En | MEDLINE | ID: mdl-36765918
Multiple myeloma (MM) is characterized by serial relapses, necessitating the application of sequential lines of therapy (LoT). Reports on attrition rates (ARs) vary widely. The present study analysed ARs from the Austrian Myeloma Registry. Attrition was defined as being either deceased, progressive without having received another LoT, or lack of follow-up for ≥5 years. A total of 571 patients diagnosed between January 2009 and August 2021 were included (median age: 72 years; median follow-up: 50.8 months). Some 507 patients received at least one LoT. Of the total, 43.6% underwent autologous stem cell transplantation (SCT, transplant eligible = TE)) with primarily VRd (Bortezomib/Lenalidomide/Dexamethasone) given as induction (26.5%), followed by lenalidomide maintenance in 55.7% of cases. Transplant-ineligible (NTE) patients were predominantly treated with Vd (Bortezomib/Dexamethasone, 21.6%), receiving maintenance in 27.1%. A total of 37.5% received a second LoT. ARs across one to five LoTs were 16.7-27%. Frontline induction/ SCT followed by maintenance reduced ARs associated with age and achievement of deep remission in the frontline. Deep remission prolongs follow-up and time-to-next-treatment (TTNT), while high-risk-cyctogenetics negatively affected these outcomes. Our results demonstrate considerably lower ARs for MM patients within the AMR data versus other healthcare systems. Young age and the achievement of significant remissions after optimal frontline therapy resulted in particularly low ARs. These promising results support a key role for the ease of drug access and reimbursement policies in governing long-term MM patient outcomes.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Suiza